ABOUT US
ABOUT

Corporate Culture

Organizational Goals Go First

  • Follow directions and do the right thing responsibly
  • Love the company and protect the interests of the company anytime and anywhere
  • Take the initiative to overcome difficulties in emergency

Challenge the Impossible

  • Set goals to maximize the work potential
  • Say no to empiricism and make the best use of the existing resources,personal abilities and past experience
  • Keep going, and make breakthroughs

Borderless Collaboration

  • Follow the project leader's assignment and pursue final achievements
  • Cross-departmental project goal goes first, followed by departmental goal
  • Quick response, follow but not be wedded to workflow

3D Medicines has an international and professional team of talents with both technical and business thinking.

It covers the professional fields of biology, pharmacy, chemistry, bioinformatics, pharmacology, pathology, FDA new drug approval and clinic, and has extensive experience in product development, marketing, business cooperation, drug development and internationalization.

  • Senior Management
  • Medicinal Development
  • Diagnosis and Data
  • Business Development
  • Simon Shung

    Ph.D. Founder & Chairman, co-CEO

    Ph.D in Institute of biochemistry and cell biology, CAS, China.

    Postdoc in UZH,Switzerland.

    Founded 3DMed in 2010, focusing on precision cancer diagnostics and drug development.

    Building up a drug pipeline covering 3 clinical late stage compounds and 1 preclinical clinical candidates.

  • John Gong

    M.D. Ph.D. CEO

    10 years as a US FDA reviewer, familiar with new drug development and international regulations

    Former VP of BeiGene, a leading oncology biopharmaceutical company in China

    Former CTO of JOINN Lab, a leading CRO in China

    Former CEO of BL Pharmaceuticals, Beijing, a prodrug platform company in China

    Ph.D. in Toxicology from New York University

    M.D. from Beijing Medical University

  • Liang Zhang

    EMBA EVP & CHO

    Over 10 years working experience in multinational and domestic companies, Rich experiences inorganization and Culture transformation

    Former VP and Chief HR Officer of CIFI Group (00884.HK)

    Former Chief HR Officer of Kyuan pharmaceutical Inc. of SPH Group

    Former CEO Assistant and HR director of Tasly Group(600535), former HR manager of Motorola(China)

    M.B.A. from CEIBS

  • Simon Xu

    Ph.D.CFA,CFO

    13 years work experience in Life Science research, and investment management in hedge fund/private equity/fund of funds, focusing on the US and Greater China healthcare markets;

    Former Executive Director of China Minsheng Investment Group, invested and managed a global healthcare portfolio of over 250 million USD and sat on boards of directors of several portfolio companies;

    Former Executive Director of China Minsheng Investment Group, invested and managed a global healthcare portfolio of over 250 million USD and sat on boards of directors of several portfolio companies;

    Former Founding Member of BioTechnique, a cytotoxic fill-finish CMO in the US, acquired by LSNE;

    Ph.D. in Genetic, Molecular and Cellular Biology from University of Southern California, CFA Charterholder, HK SFC Type 4 License holder, qualified to conduct private equity investment in China (AMAC)

  • David Liu

    MD, Ph.D.CMO,

    Engaged in research and development of oncology drugs for nearly 20 years with extensive training in both basic science and clinical medicine; Experienced in global clinical development of biologics and small molecules in both solid and blood malignancies.

    Former Executive Medical Director at Celgene USA who led a successful global submission program in the capacity of Global Lead physician; Former Group Medical Director at BMS who played leadership roles in clinical development of ipilimumab, nivolumab, brivanib, and ixabepilone.

    Authored over 20 peer reviewed clinical and basic research articles in prestigious journals including NEJM, Lancet Oncology, JCO, and PNAS; Inventor of over 10 patents.

    Obtained medical degree from Peking University Health Science Center, Master’s degree from the University of Toledo, and PhD from MIT.

  • Jeffrey Lin

    Ph.D. Sr.Director

    Leads 3DMed bio-marker discovery

    Former senior scientist of GSK, responsible for drug screening assay, with rich research experience in epigenetics and leukemia

    Ph.D. in Biochemistry and Molecular Biology from Chinese Academy of Sciences (CAS), Post-Doc from the Chinese Academy of Sciences Institute of Health

  • Meng Fu

    M.D. MBA, VP of Clinical Operation

    Over 15 years' industry experience in clinical operation across AsiaPac, North America, South America, Europe and Australia

    Former General Manager of Gleneagles CRC (China) Pte. Ltd. in China

    Former Global Clinical Operation Team Lead at GE Healthcare in US

    Former Global Project Lead at Syneos Health in US

    Former Clinical operation and Development Director at Pharmacyclics in US

    Former Senior Global Program Lead at Medimmune in US

    MBA from Ohio University, MSc from The University of Sheffield, M.D. from Jilin University, Norman Bethune Medical School

  • LeAnn Li

    M.D., Ph.D. Senior Clinical Operation Director

    15 years working experience in global clinical research and global regulatory affairs

    5 years working experience in clinical practice.

    Former Director of international R&D center of Tasly Group (600535)

    M.D. from HeBei Medical University, Master from Oklahoma State University, Ph.D. from Tianjin University

  • Walt Cao

    Ph.D. RAC, Head, Clinical Pharmacology&Pharmacometrics

    16 years work experience in new drug design, translational sciences, clinical research and development.

    Former US FDA senior clinical pharmacology reviewer and biosimilar lead for oncology drug。 Primarily reviewed and provided regulatory advice for clinical pharmacology & pharmacometrics related clinical trial design & optimization, safety and efficacy, marketing application and post-marketing life-cycle management for oncology drug in US FDA.

    Former Senior Scientist in Boehringer Ingelheim and Abbott /AbbVie;

    Ph.D. in Pharmaceutics from the Ohio State University (2007). Active US Regulatory Affairs Certificate (RAC) holder (2018-2020)

  • Haolan Lu

    Ph.D.Senior Biostatistics Director

    Over 14 years of oncology drug development experience with a proven track of success in immuno-oncology drugs global registration and approvals including two immuno-oncology pioneering drugs: Opdivo (nivolumab) and Yervoy (ipilimumab).

    Former non-small cell lung cancer indication statistical lead of Bristol-Myers Squibb Company, led registration global approvals for Opdivo in the second and third line treatment of NSCLC;

    Ph.D. in Biostatistics from University of Minnesota

  • Caifu Chen

    Ph.D. CTO IVD

    20 years of broad biotech R&D experiences in developing cutting-edge qPCR, CE, dPCR & NGS products for RUO, LDT & Dx

    Passionate R&D leader at multiple companies & countries

    Vice President of Genetic Applications R&D at Thermo Fisher in 2012 - 2014

    Vice President of Molecular Biology R&D in Pall Corporation in 2010 - 2012

    Sr. Director and Scientific Fellow at Applied Biosystems in 1998 - 2010

    Expert qPCR and NGS product developer

    Developed TaqMan MicroRNA Assays, AmpliSeq, Target Capture NGS Kits, and many other TaqMan Assays for RUO, LDT and Dx applications

    Achieving >$800M new product revenues

    Successful collaborator with hundreds of academic institutes and biotech companies in cancer, miRNAs, stem cells, CNVs & single cell analysis

    Productive author of 55 peer-reviewed papers, 8 book chapters, and holder of 36 patents and patent publications

    Molecular geneticist trained at Harvard Medical School in 1996-1998 and University of Missouri in 1993-1996

  • Fugen Li

    Ph.D.,VP, Precision Medicine R&D

    Senior expert in bioinformatics, genomics and bio-marker research

    Former senior bioinformatics scientist at Dana-Farber Cancer Institute in Boston, former CTO of Ibioinform in Boston, former senior scientist at MIT and Sanofi-Aventis

    Ph.D. in Molecular Biology from Oregon State University

  • Hank Yang

    MBA,VP,Data and Information System

    20 years of experience in software system architecture and intelligence algorithm application

    Working experience in Computing Center of Chinese Academy of Sciences, MCI Communications (US) and SAS( a leading company in analytics)

    Former CTO of a software company

    Double Master degree in Mathematics and Computer Science

  • Kangning Chen

    Sales VP of Precision Diagnosis

    18 years' experience in sales management such as generic drug and special medicine

    Worked as a respiratory physician in the Jiangsu Province Hospital after graduation and then joined Xian-Janssen, and promoted to director of One China OTC Business Division

    Graduated from Clinical Medicine, Nanjing Medical University and EMBA of CEIBS

  • Steven Cai

    Strategy Marketing, VP

    2 years experience as a clinician, 20 years experience in sales and marketing of pharmaceuticalcompany

    Held various positions in Xian-Janssen, including marketing director, strategic marketing director,national sales manager

    Bachelor in clinical medicine of Military Medical University, Zhongshan University EMBA

沪公网安备 31011202002810号